Literature DB >> 26369974

Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.

Ilias Karaiskos1, Lena E Friberg2, Konstantinos Pontikis3, Konstantinos Ioannidis4, Vasiliki Tsagkari3, Lamprini Galani5, Eirini Kostakou3, Fotini Baziaka5, Charalambos Paskalis6, Antonia Koutsoukou3, Helen Giamarellou5.   

Abstract

Colistin has been revived, in the era of extensively drug-resistant (XDR) Gram-negative infections, as the last-resort treatment in critically ill patients. Recent studies focusing on the optimal dosing strategy of colistin have demonstrated the necessity of a loading dose at treatment initiation (D. Plachouras, M. Karvanen, L. E. Friberg, E. Papadomichelakis, A. Antoniadou, I. Tsangaris, I. Karaiskos, G. Poulakou, F. Kontopidou, A. Armaganidis, O. Cars, and H. Giamarellou, Antimicrob Agents Chemother 53:3430-3436, 2009, http://dx.doi.org/10.1128/AAC.01361-08; A. F. Mohamed, I. Karaiskos, D. Plachouras, M. Karvanen, K. Pontikis, B. Jansson, E. Papadomichelakis, A. Antoniadou, H. Giamarellou, A. Armaganidis, O. Cars, and L. E. Friberg, Antimicrob Agents Chemother 56:4241- 4249, 2012, http://dx.doi.org/10.1128/AAC.06426-11; S. M. Garonzik, J. Li, V. Thamlikitkul, D. L. Paterson, S. Shoham, J. Jacob, F. P. Silveira, A. Forrest, and R. L. Nation, Antimicrob Agents Chemother 55:3284-3294, 2011, http://dx.doi.org/10.1128/AAC.01733-10). In 19 critically ill patients with suspected or microbiologically documented infections caused by XDR Gram-negative strains, a loading dose of 9 MU colistin methanesulfonate (CMS) (∼ 270 mg colistin base activity) was administered with a maintenance dose of 4.5 MU every 12 h, commenced after 24 h. Patients on renal replacement were excluded. CMS infusion was given over 30 min or 1 h. Repeated blood sampling was performed after the loading dose and after the 5th or 6th dose. Colistin concentrations and measured CMS, determined after hydrolization to colistin and including the partially sulfomethylated derivatives, were determined with a liquid chromatography-tandem mass spectrometry assay. Population pharmacokinetic analysis was conducted in NONMEM with the new data combined with data from previous studies. Measured colistimethate concentrations were described by 4 compartments for distribution and removal of sulfomethyl groups, while colistin disposition followed a 1-compartment model. The average observed maximum colistin A plus B concentration was 2.65 mg/liter after the loading dose (maximum time was 8 h). A significantly higher availability of the measured A and B forms of colistimethate and colistin explained the higher-than-expected concentrations in the present study compared to those in previous studies. Creatinine clearance was a time-varying covariate of colistimethate clearance. The incidence of acute renal injury was 20%.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26369974      PMCID: PMC4649253          DOI: 10.1128/AAC.00554-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Authors:  Ami F Mohamed; Ilias Karaiskos; Diamantis Plachouras; Matti Karvanen; Konstantinos Pontikis; Britt Jansson; Evangelos Papadomichelakis; Anastasia Antoniadou; Helen Giamarellou; Apostolos Armaganidis; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.

Authors:  Hui He; Ji-Chang Li; Roger L Nation; Jovan Jacob; Gong Chen; Hee Ji Lee; Brian T Tsuji; Philip E Thompson; Kade Roberts; Tony Velkov; Jian Li
Journal:  J Antimicrob Chemother       Date:  2013-06-07       Impact factor: 5.790

3.  The urgent need for clear and accurate information on the polymyxins.

Authors:  Roger L Nation; Jian Li; John D Turnidge
Journal:  Clin Infect Dis       Date:  2013-08-09       Impact factor: 9.079

4.  Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers.

Authors:  W Couet; N Grégoire; P Gobin; P J Saulnier; D Frasca; S Marchand; O Mimoz
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

Review 5.  Adverse reactions associated with systemic polymyxin therapy.

Authors:  Julie Ann Justo; John A Bosso
Journal:  Pharmacotherapy       Date:  2014-09-30       Impact factor: 4.705

6.  New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.

Authors:  N Grégoire; O Mimoz; B Mégarbane; E Comets; D Chatelier; S Lasocki; R Gauzit; D Balayn; P Gobin; S Marchand; W Couet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

7.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

8.  Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Authors:  D Plachouras; M Karvanen; L E Friberg; E Papadomichelakis; A Antoniadou; I Tsangaris; I Karaiskos; G Poulakou; F Kontopidou; A Armaganidis; O Cars; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

9.  High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.

Authors:  Lidia Dalfino; Filomena Puntillo; Adriana Mosca; Rosa Monno; Maria Luigia Spada; Sara Coppolecchia; Giuseppe Miragliotta; Francesco Bruno; Nicola Brienza
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

Review 10.  An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Authors:  Anand Kumar
Journal:  Virulence       Date:  2013-11-01       Impact factor: 5.882

View more
  30 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

Review 2.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

3.  Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Xingchen Bian; Xiaofen Liu; Yuancheng Chen; Daijie Chen; Jian Li; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 4.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

5.  Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.

Authors:  Cornelia B Landersdorfer; Tri-Hung Nguyen; Linh Thuy Lieu; Gary Nguyen; Robert J Bischof; Els N Meeusen; Jian Li; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

6.  Reply to Corona and Cattaneo.

Authors:  Roger L Nation; Samira M Garonzik; Visanu Thamlikitkul; Evangelos J Giamarellos-Bourboulis; Alan Forrest; David L Paterson; Jian Li; Fernanda P Silveira
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

Review 7.  Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Authors:  Thien B Tran; Tony Velkov; Roger L Nation; Alan Forrest; Brian T Tsuji; Phillip J Bergen; Jian Li
Journal:  Int J Antimicrob Agents       Date:  2016-10-18       Impact factor: 5.283

8.  A Proof-of-Concept Study of the Efficacy of Systemically Administered Polymyxins in Mouse Burn Wound Infection Caused by Multidrug-Resistant Gram-Negative Pathogens.

Authors:  Yu-Wei Lin; Ke Chen; Jiping Wang; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  Activity of Antibiotics against Pseudomonas aeruginosa in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.

Authors:  Yvan Diaz Iglesias; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.